TY - JOUR
T1 - Management of patients with liver derangement during the COVID-19 pandemic
T2 - an Asia-Pacific position statement
AU - Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic
AU - Wong, Grace Lai Hung
AU - Wong, Vincent Wai Sun
AU - Thompson, Alex
AU - Jia, Jidong
AU - Hou, Jinlin
AU - Lesmana, Cosmas Rinaldi Adithya
AU - Susilo, Adityo
AU - Tanaka, Yasuhito
AU - Chan, Wah Kheong
AU - Gane, Ed
AU - Ong-Go, Arlinking K.
AU - Lim, Seng Gee
AU - Ahn, Sang Hoon
AU - Yu, Ming Lung
AU - Piratvisuth, Teerha
AU - Chan, Henry Lik Yuen
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/8
Y1 - 2020/8
N2 - The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or both. The clinical implications of liver derangement might be variable in different clinical scenarios. With growing evidence of its clinical significance, it would be clinically helpful to provide practice recommendations for various common clinical scenarios of liver derangement during the COVID-19 pandemic. The Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic was formed to systematically review the literature with special focus on the clinical management of patients who have been or who are at risk of developing liver derangement during this pandemic. Clinical scenarios covering the use of pharmacological treatment for COVID-19 in the case of liver derangement, and assessment and management of patients with chronic hepatitis B or hepatitis C, non-alcoholic fatty liver disease, liver cirrhosis, and liver transplantation during the pandemic are discussed.
AB - The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or both. The clinical implications of liver derangement might be variable in different clinical scenarios. With growing evidence of its clinical significance, it would be clinically helpful to provide practice recommendations for various common clinical scenarios of liver derangement during the COVID-19 pandemic. The Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic was formed to systematically review the literature with special focus on the clinical management of patients who have been or who are at risk of developing liver derangement during this pandemic. Clinical scenarios covering the use of pharmacological treatment for COVID-19 in the case of liver derangement, and assessment and management of patients with chronic hepatitis B or hepatitis C, non-alcoholic fatty liver disease, liver cirrhosis, and liver transplantation during the pandemic are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85087752683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087752683&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(20)30190-4
DO - 10.1016/S2468-1253(20)30190-4
M3 - Review article
C2 - 32585136
AN - SCOPUS:85087752683
SN - 2468-1253
VL - 5
SP - 776
EP - 787
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 8
ER -
